Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746

Medical Mycology

Volumn 38, Issue 3, 2000, Pages 221-224

  Restrepo, M I ^a   Najvar, L K ^a   Barchiesi, F ^a   Luther, M F ^b   Graybill, John R ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Fluconazole; Murine cryptococcal meningitis

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 3 METHYL 2 (1H 1,2,4 TRIAZOL 1 YL) 4 [4 (TRIFLUOROMETHYL)BENZOYL]MORPHOLINE; 2 (2,4 DIFLUOROPHENYL) 6 HYDROXY 3 METHYL 2 (1H 1,2,4 TRIAZOL 1 YL) 4 [4 (TRIFLUOROMETHYL)BENZOYL]MORPHOLINE; ANTIFUNGAL AGENT; FLUCONAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FUNGAL MENINGITIS; MALE; MOUSE; NONHUMAN; SURVIVAL;

ANIMALIA; FILOBASIDIELLA NEOFORMANS; MURINAE;

EID: 0034122235     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.38.3.221.224     Document Type: Article

References (12)

1. Powderly WG. Therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1992; 14 (S1): S54-59.
2. Zuger A, Schuster M, Simberkoff MS, Rahal JJ, Holzman RS. Maintenance amphotericin B for cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109: 592-593.
3. Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993; 37: 1383-1386.
4. Khanlou H, Salmon D, Paugam A, et al. Factors of failure in fluconazole (FCZ) therapy of oral and esophageal candidiasis in HIV-infected patients (pts). In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. CA, September 1995. Washington. DC: American Society for Microbiology, 1995: abstract E62.
5. Velez JD, Allendorfer R, Luther M, Rinaldi MG, Graybill JR. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis 1993; 168: 508-510.
6. Bartroli J, Turmo E, Alguero M, et al. Synthesis and antifungal activity of new azole derivatives containing on N-acylmorpho-line ring. J Med Chem 1995; 38: 3918-3932.
7. Bornay-Llinares FJ, Torres-Rodriguez JM. Anticryptococcal meningitis activity of a new azole derivative (UR-9746) in a murine model. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washington, DC: American Society for Microbiology, 1995: abstract F86.
8. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts: proposed standard M27-P. National Committee for Clinical Laboratory Standards: Villanova, PA, 1992.
9. Clemons KV, Stevens DA. Efficacy of UR-9746 and UR-9751 against coccidioidomycosis. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washington, DC: American Society of Microbiology, 1995: abstract B70.
10. Stevens DA, Devine MJ, Martinez M, Aristizabal B. In vitro antifungal activity of novel azole derivatives with a morpholine ring. UR-9746 (U46) and UR-9751 (UR51): comparison with fluconazole (F). In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 1995. Washington, DC: American Society of Microbiology, 1995: abstract F85.
11. Improvisi L, Garcia-Hermoso D, Provost F, Dupont B. Evaluation of two novel antifungal agents, UR-9746 and UR-9751 in the treatment of experimental murine histoplasmosis. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washington, DC: American Society of Microbiology, 1995: abstract F89.
12. Bornay-Llinares FJ, Mayol-Belda MS, Onrubia-Pintado J, Torres-Rodriguez JM. Murine cryptococcosis. Tissular damage decrease after treatment with UR-9746. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washington, DC: American Society for Microbiology, 1995: abstract F88.